BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Okanoue T, Sakamoto S, Itoh Y, Minami M, Yasui K, Sakamoto M, Nishioji K, Katagishi T, Nakagawa Y, Tada H. Side effects of high-dose interferon therapy for chronic hepatitis C. J Hepatol. 1996;25:283-291. [PMID: 8895006 DOI: 10.1016/s0168-8278(96)80113-9] [Cited by in Crossref: 282] [Cited by in F6Publishing: 242] [Article Influence: 11.3] [Reference Citation Analysis]
Number Citing Articles
1 Wang L, Li B, Zhao H, Wu P, Wu Q, Chen K, Mu Y. A systematic review and meta-analysis of endocrine-related adverse events associated with interferon. Front Endocrinol 2022;13:949003. [DOI: 10.3389/fendo.2022.949003] [Reference Citation Analysis]
2 Wang L, Chen K, Wang M, Lv Z, Gu W, Wang X, Ni Q, Mu Y. Characteristics of Interferon-Associated Diabetes Mellitus in Past 30 Years: A Review. Horm Metab Res 2022;54:145-52. [PMID: 35276739 DOI: 10.1055/a-1749-5716] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Sirobhushanam S, Lazar S, Kahlenberg JM. Interferons in Systemic Lupus Erythematosus. Rheum Dis Clin North Am 2021;47:297-315. [PMID: 34215365 DOI: 10.1016/j.rdc.2021.04.001] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
4 Vinh DC, Abel L, Bastard P, Cheng MP, Condino-Neto A, Gregersen PK, Haerynck F, Cicalese MP, Hagin D, Soler-Palacín P, Planas AM, Pujol A, Notarangelo LD, Zhang Q, Su HC, Casanova JL, Meyts I; COVID Human Genetic Effort. Harnessing Type I IFN Immunity Against SARS-CoV-2 with Early Administration of IFN-β. J Clin Immunol 2021. [PMID: 34101091 DOI: 10.1007/s10875-021-01068-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
5 Shao YY, Cheng AL, Hsu CH. An Underdiagnosed Hypothyroidism and Its Clinical Significance in Patients with Advanced Hepatocellular Carcinoma. Oncologist 2021;26:422-6. [PMID: 33687750 DOI: 10.1002/onco.13755] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Matzner P, Sandbank E, Neeman E, Zmora O, Gottumukkala V, Ben-Eliyahu S. Harnessing cancer immunotherapy during the unexploited immediate perioperative period. Nat Rev Clin Oncol 2020;17:313-26. [PMID: 32066936 DOI: 10.1038/s41571-019-0319-9] [Cited by in Crossref: 15] [Cited by in F6Publishing: 28] [Article Influence: 7.5] [Reference Citation Analysis]
7 Lazear HM, Schoggins JW, Diamond MS. Shared and Distinct Functions of Type I and Type III Interferons. Immunity 2019;50:907-23. [PMID: 30995506 DOI: 10.1016/j.immuni.2019.03.025] [Cited by in Crossref: 267] [Cited by in F6Publishing: 353] [Article Influence: 89.0] [Reference Citation Analysis]
8 Gull I, Aslam MS, Tipu I, Mushtaq R, Ali TZ, Athar MA. Development of latent Interferon alpha 2b as a safe therapeutic for treatment of Hepatitis C virus infection. Sci Rep 2019;9:10867. [PMID: 31350425 DOI: 10.1038/s41598-019-47074-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
9 Wahid B. An unusual case of renal dysfunction and hepatocellular carcinoma following sofosbuvir therapy. Future Virology 2019;14:461-4. [DOI: 10.2217/fvl-2018-0158] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
10 Sakamaki A, Kamimura K, Fukui N, Watanabe H, Sakai N, Tominaga K, Mizuno K, Takamura M, Kawai H, Sugai T, Yamagiwa S, Someya T, Terai S. A case report of psychiatric symptoms following direct-acting antiviral and ribavirin combination therapy for chronic hepatitis C in a patient with innate anxiety. BMC Gastroenterol 2019;19:85. [PMID: 31195993 DOI: 10.1186/s12876-019-1013-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
11 Allard FD, Stelow EB. Review of Drug-induced Injury in Mucosal Biopsies From the Tubular Gastrointestinal Tract. Adv Anat Pathol 2019;26:151-70. [PMID: 30870181 DOI: 10.1097/PAP.0000000000000230] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
12 Tung CH, Lai NS, Li CY, Tsai SJ, Chen YC, Chen YC. Risk of rheumatoid arthritis in patients with hepatitis C virus infection receiving interferon-based therapy: a retrospective cohort study using the Taiwanese national claims database. BMJ Open 2018;8:e021747. [PMID: 30037875 DOI: 10.1136/bmjopen-2018-021747] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
13 Ismail EI, Morgan AE, Farag RE. Assessment of auditory functions in chronic hepatitis C patients treated by sofosbuvir. J Otol 2018;13:10-5. [PMID: 29937860 DOI: 10.1016/j.joto.2017.11.001] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
14 Nishio K, Arase T, Tada H, Tachibana H. Interferon related pericarditis: Review. World J Cardiol 2017; 9(6): 553-557 [PMID: 28706591 DOI: 10.4330/wjc.v9.i6.553] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
15 Arriens C, Wren JD, Munroe ME, Mohan C. Systemic lupus erythematosus biomarkers: the challenging quest. Rheumatology (Oxford) 2017;56:i32-45. [PMID: 28013203 DOI: 10.1093/rheumatology/kew407] [Cited by in Crossref: 16] [Cited by in F6Publishing: 32] [Article Influence: 3.2] [Reference Citation Analysis]
16 Arooj M, Malik A, Basit A, Husain Qazi M, Asif M, Sarwar Jamal M, Mostafa Mahmoud M, Choudhry H, Natesan Pushparaj P, Rasool M. Implications of prognostic variables in the assessment of autoimmunity in hepatitis C patients receiving interferon therapy. Bioinformation 2016;12:131-4. [PMID: 28149047 DOI: 10.6026/97320630012131] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
17 Fathallah N, Slim R, Larif S, Hmouda H, Ben Salem C. Drug-Induced Hyperglycaemia and Diabetes. Drug Saf. 2015;38:1153-1168. [PMID: 26370106 DOI: 10.1007/s40264-015-0339-z] [Cited by in Crossref: 65] [Cited by in F6Publishing: 67] [Article Influence: 10.8] [Reference Citation Analysis]
18 Bishay RH, Chen RC. Hashimoto's Thyroiditis and Graves' Disease in One Patient: The Extremes of Thyroid Dysfunction Associated with Interferon Treatment. Case Rep Endocrinol 2016;2016:6029415. [PMID: 27042364 DOI: 10.1155/2016/6029415] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
19 Alkan E, Akin M, Adanir H, Tuna Y. Interstitial Pneumonitis Related to Pegylated Interferon Alfa-2a Treatment in a Patient with Chronic Hepatitis C. Euroasian J Hepatogastroenterol 2016;6:91-2. [PMID: 29201735 DOI: 10.5005/jp-journals-10018-1176] [Reference Citation Analysis]
20 Hwang Y, Kim W, Kwon SY, Yu HM, Kim JH, Choe WH. Incidence of and risk factors for thyroid dysfunction during peginterferon α and ribavirin treatment in patients with chronic hepatitis C. Korean J Intern Med 2015;30:792-800. [PMID: 26552454 DOI: 10.3904/kjim.2015.30.6.792] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
21 Palma-Ocampo HK, Flores-Alonso JC, Vallejo-Ruiz V, Reyes-Leyva J, Flores-Mendoza L, Herrera-Camacho I, Rosas-Murrieta NH, Santos-López G. Interferon lambda inhibits dengue virus replication in epithelial cells. Virol J 2015;12:150. [PMID: 26411318 DOI: 10.1186/s12985-015-0383-4] [Cited by in Crossref: 35] [Cited by in F6Publishing: 38] [Article Influence: 5.0] [Reference Citation Analysis]
22 Hammerstad SS, Grock SF, Lee HJ, Hasham A, Sundaram N, Tomer Y. Diabetes and Hepatitis C: A Two-Way Association. Front Endocrinol (Lausanne). 2015;6:134. [PMID: 26441826 DOI: 10.3389/fendo.2015.00134] [Cited by in Crossref: 47] [Cited by in F6Publishing: 50] [Article Influence: 6.7] [Reference Citation Analysis]
23 Baldo BA. Side effects of cytokines approved for therapy. Drug Saf 2014;37:921-43. [PMID: 25270293 DOI: 10.1007/s40264-014-0226-z] [Cited by in Crossref: 75] [Cited by in F6Publishing: 77] [Article Influence: 10.7] [Reference Citation Analysis]
24 Scott N, Hellard M, McBryde ES. Modeling hepatitis C virus transmission among people who inject drugs: Assumptions, limitations and future challenges. Virulence 2016;7:201-8. [PMID: 26305706 DOI: 10.1080/21505594.2015.1085151] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
25 Zhuang H, Szeto C, Han S, Yang L, Reeves WH. Animal Models of Interferon Signature Positive Lupus. Front Immunol 2015;6:291. [PMID: 26097482 DOI: 10.3389/fimmu.2015.00291] [Cited by in Crossref: 40] [Cited by in F6Publishing: 41] [Article Influence: 5.7] [Reference Citation Analysis]
26 Sakatani A, Doi Y, Matsuda T, Sasai Y, Nishida N, Sakamoto M, Uenoyama N, Matsumoto Y, Kinoshita K. Protracted anaphylaxis developed after peginterferon α-2a administration for chronic hepatitis C. World J Gastroenterol 2015; 21(9): 2826-2829 [PMID: 25759556 DOI: 10.3748/wjg.v21.i9.2826] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
27 Li H, Feng YG, Zhang HM, Zhang XQ, Zhong H, Ge ZY. Meta-analysis of utility of type Ⅰ interferons in treatment of ulcerative colitis. Shijie Huaren Xiaohua Zazhi 2015; 23(6): 1005-1010 [DOI: 10.11569/wcjd.v23.i6.1005] [Reference Citation Analysis]
28 Tarhini AA, Shin D, Lee SJ, Stuckert J, Sander CA, Kirkwood JM. Serologic evidence of autoimmunity in E2696 and E1694 patients with high-risk melanoma treated with adjuvant interferon alfa. Melanoma Res 2014;24:150-7. [PMID: 24509407 DOI: 10.1097/CMR.0000000000000050] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
29 Kessing CF, Tyor WR. Interferon-α induces neurotoxicity through activation of the type I receptor and the GluN2A subunit of the NMDA receptor. J Interferon Cytokine Res 2015;35:317-24. [PMID: 25517826 DOI: 10.1089/jir.2014.0105] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
30 Galli L, Gerdes VE, Guasti L, Squizzato A. Thrombosis Associated with Viral Hepatitis. J Clin Transl Hepatol. 2014;2:234-239. [PMID: 26357629 DOI: 10.14218/jcth.2014.00031] [Cited by in Crossref: 8] [Cited by in F6Publishing: 15] [Article Influence: 1.0] [Reference Citation Analysis]
31 Vasilij Benatti S, Giampaolo Q, Sara B, Marco R, Diego R. Pulmonary complications associated with pegylated interferon and ribavirin in HIV/hepatitis C virus coinfected patients. AIDS 2014;28:2633-5. [PMID: 25574965 DOI: 10.1097/QAD.0000000000000464] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
32 Antonelli A, Ferrari SM, Giuggioli D, Di Domenicantonio A, Ruffilli I, Corrado A, Fabiani S, Marchi S, Ferri C, Ferrannini E, Fallahi P. Hepatitis C virus infection and type 1 and type 2 diabetes mellitus. World J Diabetes 2014; 5(5): 586-600 [PMID: 25317237 DOI: 10.4239/wjd.v5.i5.586] [Cited by in CrossRef: 62] [Cited by in F6Publishing: 56] [Article Influence: 7.8] [Reference Citation Analysis]
33 Sato A, Yamauchi M, Yamada T, Kumano R, Adachi K, Ishii T, Hayashi M, Kumon D. Successful natural interferon-β plus ribavirin therapy in a chronic hepatitis C patient after discontinuation of interferon-α treatment due to arrhythmia and interstitial pneumonia. Clin J Gastroenterol 2014;7:355-60. [PMID: 25132867 DOI: 10.1007/s12328-014-0500-8] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
34 Uhl P, Fricker G, Haberkorn U, Mier W. Current status in the therapy of liver diseases. Int J Mol Sci. 2014;15:7500-7512. [PMID: 24786290 DOI: 10.3390/ijms15057500] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 3.0] [Reference Citation Analysis]
35 Hakim FA, Singh S, Pandit A, Alegria JR, Camoriano J, Stanton ML, Mookadam F. Interferon-α and pericardial injury: a case report and literature review. Heart Asia 2014;6:48-53. [PMID: 27326167 DOI: 10.1136/heartasia-2013-010488] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
36 O’Day R, Gillies MC, Ahlenstiel G. Ophthalmologic complications of antiviral therapy in hepatitis C treatment. World J Gastroenterol 2013; 19(45): 8227-8237 [PMID: 24363513 DOI: 10.3748/wjg.v19.i45.8227] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
37 Kawazoe T, Araki M, Lin Y, Ogawa M, Okamoto T, Yamamura T, Wakakura M, Murata M. New-onset type 1 diabetes mellitus and anti-aquaporin-4 antibody positive optic neuritis associated with type 1 interferon therapy for chronic hepatitis C. Intern Med 2012;51:2625-9. [PMID: 22989839 DOI: 10.2169/internalmedicine.51.7771] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
38 Nair Kesavachandran C, Haamann F, Nienhaus A. Frequency of thyroid dysfunctions during interferon alpha treatment of single and combination therapy in hepatitis C virus-infected patients: a systematic review based analysis. PLoS One. 2013;8:e55364. [PMID: 23383326 DOI: 10.1371/journal.pone.0055364] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
39 Selcukbiricik F, Tural D, Senel TE, Sarıca A, Soyluk O, Serdengecti S. Bilateral Ischemic Optic Neuropathy Developed under Interferon Therapy. Case Rep Ophthalmol Med 2012;2012:102739. [PMID: 23119208 DOI: 10.1155/2012/102739] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
40 Petousi N, Thomas EC. Interferon-β-induced pulmonary sarcoidosis in a 30-year-old woman treated for multiple sclerosis: a case report. J Med Case Rep 2012;6:344. [PMID: 23043877 DOI: 10.1186/1752-1947-6-344] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
41 Baik SJ, Kim TH, Yoo K, Moon IH, Cho MS. Ischemic colitis during interferon-ribavirin therapy for chronic hepatitis C: A case report. World J Gastroenterol 2012; 18(31): 4233-4236 [PMID: 22919260 DOI: 10.3748/wjg.v18.i31.4233] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
42 Kiefer K, Oropallo MA, Cancro MP, Marshak-Rothstein A. Role of type I interferons in the activation of autoreactive B cells. Immunol Cell Biol 2012;90:498-504. [PMID: 22430248 DOI: 10.1038/icb.2012.10] [Cited by in Crossref: 111] [Cited by in F6Publishing: 117] [Article Influence: 11.1] [Reference Citation Analysis]
43 Monzon JG, Hammad N, Stevens SD, Dancey J. Retinopathy associated with adjuvant high-dose interferon-α2b in a patient with resected melanoma: a case report and review of the literature. Oncologist 2012;17:384-7. [PMID: 22334452 DOI: 10.1634/theoncologist.2011-0324] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
44 Hamnvik OP, Larsen PR, Marqusee E. Thyroid dysfunction from antineoplastic agents. J Natl Cancer Inst 2011;103:1572-87. [PMID: 22010182 DOI: 10.1093/jnci/djr373] [Cited by in Crossref: 104] [Cited by in F6Publishing: 72] [Article Influence: 9.5] [Reference Citation Analysis]
45 Smith KJ, Norris S, O'Farrelly C, O'Mara SM. Risk factors for the development of depression in patients with hepatitis C taking interferon-α. Neuropsychiatr Dis Treat. 2011;7:275-292. [PMID: 21654873 DOI: 10.2147/NDT.S13917] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 2.1] [Reference Citation Analysis]
46 Mamori S, Mamori H. Hepatitis C-related cirrhosis with sustained prevention of hepatocellular carcinoma recurrence by long-term administration of super-low-dose peginterferon-alpha 2b. Case Rep Gastroenterol 2011;5:56-62. [PMID: 21537363 DOI: 10.1159/000323692] [Reference Citation Analysis]
47 Nishio K, Konndo T, Okada S, Enchi M. Pericarditis and chronic inflammatory demyelinating polyneuropathy during therapy with pegylated interferon alfa-2a for chronic hepatitis C. World J Hepatol 2010; 2(9): 358-361 [PMID: 21161021 DOI: 10.4254/wjh.v2.i9.358] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
48 Ji FP, Li ZX, Deng H, Xue HA, Liu Y, Li M. Diagnosis and management of interstitial pneumonitis associated with interferon therapy for chronic hepatitis C. World J Gastroenterol 2010; 16(35): 4394-4399 [PMID: 20845505 DOI: 10.3748/wjg.v16.i35.4394] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
49 Heiligenhaus A, Thurau S, Hennig M, Grajewski RS, Wildner G. Anti-inflammatory treatment of uveitis with biologicals: new treatment options that reflect pathogenetic knowledge of the disease. Graefes Arch Clin Exp Ophthalmol 2010;248:1531-51. [PMID: 20737162 DOI: 10.1007/s00417-010-1485-8] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 2.4] [Reference Citation Analysis]
50 Berg KT, Nelson B, Harrison AR, McLoon LK, Lee MS. Pegylated interferon alpha-associated optic neuropathy. J Neuroophthalmol 2010;30:117-22. [PMID: 20351572 DOI: 10.1097/WNO.0b013e3181d8e4af] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
51 Hall JC, Rosen A. Type I interferons: crucial participants in disease amplification in autoimmunity. Nat Rev Rheumatol. 2010;6:40-49. [PMID: 20046205 DOI: 10.1038/nrrheum.2009.237] [Cited by in Crossref: 161] [Cited by in F6Publishing: 157] [Article Influence: 13.4] [Reference Citation Analysis]
52 Abushahba W, Balan M, Castaneda I, Yuan Y, Reuhl K, Raveche E, de la Torre A, Lasfar A, Kotenko SV. Antitumor activity of type I and type III interferons in BNL hepatoma model. Cancer Immunol Immunother 2010;59:1059-71. [PMID: 20217081 DOI: 10.1007/s00262-010-0831-3] [Cited by in Crossref: 67] [Cited by in F6Publishing: 74] [Article Influence: 5.6] [Reference Citation Analysis]
53 Kong YC, Wei WZ, Tomer Y. Opportunistic autoimmune disorders: from immunotherapy to immune dysregulation. Ann N Y Acad Sci 2010;1183:222-36. [PMID: 20146718 DOI: 10.1111/j.1749-6632.2009.05138.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.6] [Reference Citation Analysis]
54 Barut S, Karaer H, Oksuz E, Eken AG, Basak AN. Bell’s palsy and choreiform movements during peginterferon α and ribavirin therapy. World J Gastroenterol 2009; 15(29): 3694-3696 [PMID: 19653353 DOI: 10.3748/wjg.15.3694] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
55 Gonzalez G, Castro FP, Berho M, Petras R. Autoimmune enteropathy associated with cessation of interferon-alpha therapy in chronic hepatitis C. Dig Dis Sci 2010;55:1490-3. [PMID: 19639409 DOI: 10.1007/s10620-009-0877-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
56 El-Atrebi K, El-Bassyouni HT. Management of rare side effects of peginterferon and ribavirin therapy during hepatitis C treatment: a case report. Cases J 2009;2:7429. [PMID: 19829962 DOI: 10.4076/1757-1626-2-7429] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
57 Tsianakas A, Schiller M, Luger TA, Sunderkoetter C. Adjuvant interferon therapy and rheumatoid arthritis--a contraindication? Acta Oncol 2009;48:468-9. [PMID: 18759142 DOI: 10.1080/02841860802314753] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
58 Slavenburg S, Heijdra YF, Drenth JP. Pneumonitis as a consequence of (peg)interferon-ribavirin combination therapy for hepatitis C: a review of the literature. Dig Dis Sci. 2010;55:579-585. [PMID: 19399621 DOI: 10.1007/s10620-009-0797-1] [Cited by in Crossref: 38] [Cited by in F6Publishing: 30] [Article Influence: 2.9] [Reference Citation Analysis]
59 Atug O, Akin H, Alahdab YO, Ceyhan B, Tozun N, Ozdogan O. Interstitial pneumonitis associated with pegylated interferon-alpha 2a and ribavirin for chronic hepatitis C infection: a case report. Cases J 2009;2:6464. [PMID: 20181162 DOI: 10.1186/1757-1626-0002-0000006464] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
60 Soetekouw PM, Koopman M, Burger D, Tjan-Heijnen VC, De Mulder PH. Severe hyponatremia caused by hyperglycaemia due to interferon alpha therapy in advanced renal cell carcinoma. Acta Oncol 2009;48:154-6. [PMID: 19101828 DOI: 10.1080/02841860802047403] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
61 Rodríguez Carballeira M, de Juan C, Reverter JC. [Bilateral suprarenal hematoma in a 46-year-old male]. Med Clin (Barc) 2008;130:71-7. [PMID: 18221678 DOI: 10.1157/13115030] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
62 Tomer Y, Blackard JT, Akeno N. Interferon alpha treatment and thyroid dysfunction. Endocrinol Metab Clin North Am. 2007;36:1051-1066; x-xi. [PMID: 17983936 DOI: 10.1016/j.ecl.2007.07.001] [Cited by in Crossref: 92] [Cited by in F6Publishing: 84] [Article Influence: 6.6] [Reference Citation Analysis]
63 Kartal ED, Alpat SN, Ozgunes I, Usluer G. Adverse effects of high-dose interferon-alpha-2a treatment for chronic hepatitis B. Adv Ther 2007;24:963-71. [PMID: 18029321 DOI: 10.1007/BF02877700] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 0.6] [Reference Citation Analysis]
64 Hass DJ, Kozuch P, Brandt LJ. Pharmacologically mediated colon ischemia. Am J Gastroenterol 2007;102:1765-80. [PMID: 17488249 DOI: 10.1111/j.1572-0241.2007.01260.x] [Cited by in Crossref: 51] [Cited by in F6Publishing: 42] [Article Influence: 3.4] [Reference Citation Analysis]
65 Hernandez L, Johnson TC, Naiyer AJ, Kryszak D, Ciaccio EJ, Min A, Bodenheimer HC, Brown RS, Fasano A, Green PH. Chronic hepatitis C virus and celiac disease, is there an association? Dig Dis Sci. 2008;53:256-261. [PMID: 17549632 DOI: 10.1007/s10620-007-9851-z] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
66 Soultati AS, Dourakis SP, Alexopoulou A, Deutsch M, Archimandritis AJ. Simultaneous development of diabetic ketoacidosis and Hashitoxicosis in a patient treated with pegylated interferon-alpha for chronic hepatitis C. World J Gastroenterol 2007; 13(8): 1292-1294 [PMID: 17451219 DOI: 10.3748/wjg.v13.i8.1292] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
67 Leung Y, Urbanski SJ, Schindel L, Myers RP. Ischemic colitis during pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Can J Gastroenterol 2006;20:661-3. [PMID: 17066158 DOI: 10.1155/2006/687836] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
68 Lodato F, Tamé MR, Colecchia A, Racchini C, Azzaroli F, D’Errico A, Casanova S, Pinna A, Roda E, Mazzella G. Systemic lupus erythematosus following virological response to peginterferon alfa-2b in a transplanted patient with chronic hepatitis C recurrence. World J Gastroenterol 2006; 12(26): 4253-4255 [PMID: 16830387 DOI: 10.3748/wjg.v12.i26.4253] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 11] [Article Influence: 0.6] [Reference Citation Analysis]
69 Mandac JC, Chaudhry S, Sherman KE, Tomer Y. The clinical and physiological spectrum of interferon-alpha induced thyroiditis: toward a new classification. Hepatology 2006;43:661-72. [PMID: 16557537 DOI: 10.1002/hep.21146] [Cited by in Crossref: 128] [Cited by in F6Publishing: 102] [Article Influence: 8.0] [Reference Citation Analysis]
70 Tran HA, Jones TL, Batey RG. The spectrum of thyroid dysfunction in an Australian hepatitis C population treated with combination Interferon-alpha2beta and Ribavirin. BMC Endocr Disord 2005;5:8. [PMID: 16219106 DOI: 10.1186/1472-6823-5-8] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 0.9] [Reference Citation Analysis]
71 Wong VK, Cheong-Lee C, Ford JAE, Yoshida EM. Acute sensorineural hearing loss associated with peginterferon and ribavirin combination therapy during hepatitis C treatment: Outcome after resumption of therapy. World J Gastroenterol 2005; 11(34): 5392-5393 [PMID: 16149154 DOI: 10.3748/wjg.v11.i34.5392] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
72 Pap T, Gay RE, Gay S. Do antivirals have any utility in the treatment of arthritis? Expert Opin Investig Drugs 1998;7:1841-8. [PMID: 15991933 DOI: 10.1517/13543784.7.11.1841] [Reference Citation Analysis]
73 Kendirli T, Kismet E, Demirkaya E, Aydin HI, Kesik V, Köseoğlu V. Death possibly associated with interferon use in a patient with chronic hepatitis. Acta Paediatr 2005;94:984-5. [PMID: 16188832 DOI: 10.1111/j.1651-2227.2005.tb02028.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
74 Raison CL, Demetrashvili M, Capuron L, Miller AH. Neuropsychiatric adverse effects of interferon-alpha: recognition and management. CNS Drugs. 2005;19:105-123. [PMID: 15697325 DOI: 10.2165/00023210-200519020-00002] [Cited by in Crossref: 331] [Cited by in F6Publishing: 297] [Article Influence: 19.5] [Reference Citation Analysis]
75 Tabaru A, Narita R, Hiura M, Abe S, Otsuki M. Efficacy of short-term interferon therapy for patients infected with hepatitis C virus genotype 2a. Am J Gastroenterol 2005;100:862-7. [PMID: 15784033 DOI: 10.1111/j.1572-0241.2005.40826.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
76 Cappell MS. Colonic toxicity of administered drugs and chemicals. Am J Gastroenterol 2004;99:1175-90. [PMID: 15180742 DOI: 10.1111/j.1572-0241.2004.30192.x] [Cited by in Crossref: 118] [Cited by in F6Publishing: 83] [Article Influence: 6.6] [Reference Citation Analysis]
77 Chan WB, Chow CC, Cockram CS. Interferon alpha treatment and endocrine disease. J R Soc Med 2003;96:481-5. [PMID: 14519723 DOI: 10.1258/jrsm.96.10.481] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 0.5] [Reference Citation Analysis]
78 Chen LK, Hwang SJ, Tsai ST, Luo JC, Lee SD, Chang FY. Glucose intolerance in Chinese patients with chronic hepatitis C. World J Gastroenterol 2003; 9(3): 505-508 [PMID: 12632506 DOI: 10.3748/wjg.v9.i3.505] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 15] [Article Influence: 0.7] [Reference Citation Analysis]
79 Kumar KS, Russo MW, Borczuk AC, Brown M, Esposito SP, Lobritto SJ, Jacobson IM, Brown RS Jr. Significant pulmonary toxicity associated with interferon and ribavirin therapy for hepatitis C. Am J Gastroenterol 2002;97:2432-40. [PMID: 12358269 DOI: 10.1111/j.1572-0241.2002.05999.x] [Cited by in Crossref: 57] [Cited by in F6Publishing: 49] [Article Influence: 2.9] [Reference Citation Analysis]
80 Mofredj A, Howaizi M, Grasset D, Licht H, Loison S, Devergie B, Demontis R, Cadranel JF. Diabetes mellitus during interferon therapy for chronic viral hepatitis. Dig Dis Sci. 2002;47:1649-1654. [PMID: 12141831 DOI: 10.1023/A:1015852110353] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 1.4] [Reference Citation Analysis]
81 Jain K, Lam WC, Waheeb S, Thai Q, Heathcote J. Retinopathy in chronic hepatitis C patients during interferon treatment with ribavirin. Br J Ophthalmol. 2001;85:1171-1173. [PMID: 11567959 DOI: 10.1136/bjo.85.10.1171] [Cited by in Crossref: 62] [Cited by in F6Publishing: 57] [Article Influence: 3.0] [Reference Citation Analysis]
82 Wesche B, Jaeckel E, Trautwein C, Wedemeyer H, Falorni A, Frank H, von zur Mühlen A, Manns MP, Brabant G. Induction of autoantibodies to the adrenal cortex and pancreatic islet cells by interferon alpha therapy for chronic hepatitis C. Gut 2001;48:378-83. [PMID: 11171829 DOI: 10.1136/gut.48.3.378] [Cited by in Crossref: 46] [Cited by in F6Publishing: 41] [Article Influence: 2.2] [Reference Citation Analysis]
83 Shirai T, Honjo Y, Takashima M, Takayanagi S, Chida K, Nakamura H. Effect of interferon-α on pulmonary function and airway responsiveness in patients with chronic hepatitis C. Allergology International 2001;50:331-5. [DOI: 10.1046/j.1440-1592.2001.00235.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
84 Manzano alonso M, Muñoz gómez R, Castellano tortajada G, Solis herruzo J. Anosmia y ageusia inducidas por el interferón en la hepatitis crónica c. Gastroenterología y Hepatología 2001;24:412. [DOI: 10.1016/s0210-5705(01)70213-0] [Reference Citation Analysis]
85 Zdilar D, Franco-Bronson K, Buchler N, Locala JA, Younossi ZM. Hepatitis C, interferon alfa, and depression. Hepatology 2000;31:1207-11. [PMID: 10827143 DOI: 10.1053/jhep.2000.7880] [Cited by in Crossref: 160] [Cited by in F6Publishing: 151] [Article Influence: 7.3] [Reference Citation Analysis]
86 Alfurayh O, Sabeel A, Al Ahdal MN, Almeshari K, Kessie G, Hamid M, Dela Cruz DM. Hand contamination with hepatitis C virus in staff looking after hepatitis C-positive hemodialysis patients. Am J Nephrol 2000;20:103-6. [PMID: 10773609 DOI: 10.1159/000013565] [Cited by in Crossref: 55] [Cited by in F6Publishing: 47] [Article Influence: 2.5] [Reference Citation Analysis]
87 Manesis EK, Moschos M, Brouzas D, Kotsiras J, Petrou C, Theodosiadis G, Hadziyannis S. Neurovisual impairment: a frequent complication of alpha-interferon treatment in chronic viral hepatitis. Hepatology 1998;27:1421-7. [PMID: 9581701 DOI: 10.1002/hep.510270533] [Cited by in Crossref: 42] [Cited by in F6Publishing: 36] [Article Influence: 1.8] [Reference Citation Analysis]
88 Chow WC, Boyer N, Pouteau M, Castelnau C, Martinot-Peignoux M, Martins-Amado V, Degos F, Maghinici C, Sinegre M, Benhamou JP, Degott C, Erlinger S, Marcellin P. Re-treatment with interferon alfa of patients with chronic hepatitis C. Hepatology 1998;27:1144-8. [PMID: 9537456 DOI: 10.1002/hep.510270432] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 1.0] [Reference Citation Analysis]